Agtr1atm1Uky/Agtr1atm1Uky
Ldlrtm1Her/Ldlrtm1Her
Tg(Tagln-cre)1Her/0
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N * SJL
|
normal
cardiovascular system phenotype |
J:170230
|
Agtr1atm1Uky/Agtr1atm1Uky
Ldlrtm1Her/Ldlrtm1Her
Tg(Tek-cre)12Flv/0
involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6N
|
abnormal aorta elastic fiber morphology |
J:170230
|
|
abnormal ascending aorta morphology |
J:170230
|
|
decreased aorta wall thickness |
J:170230
|
|
decreased susceptibility to induced aneurysm formation |
J:170230
|
Agtr1atm1Unc/Agtr1atm1Unc
Ldlrtm1Her/Ldlrtm1Her
B6.129-Ldlrtm1Her Agtr1atm1Unc
|
decreased susceptibility to induced aneurysm formation |
J:170230
|
Aldoctm1.1(KOMP)Vlcg/Aldoctm1.1(KOMP)Vlcg
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6J * C57BL/6N
|
decreased body weight |
J:346664
|
|
decreased circulating cholesterol level |
J:346664
|
|
decreased circulating LDL cholesterol level |
J:346664
|
|
decreased circulating triglyceride level |
J:346664
|
|
decreased liver cholesterol level |
J:346664
|
|
decreased liver triglyceride level |
J:346664
|
|
decreased liver weight |
J:346664
|
Alox15tm1Fun/Alox15tm1Fun
Ldlrtm1Her/Ldlrtm1Her
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6
|
decreased susceptibility to atherosclerosis |
J:86385
|
Angptl3tm1Lex/Angptl3tm1Lex
Ldlrtm1Her/Ldlrtm1Her
involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6
|
decreased circulating cholesterol level |
J:149912
|
|
decreased circulating triglyceride level |
J:149912
|
Apoa1tm1Unc/Apoa1tm1Unc
Ldlrtm1Her/Ldlrtm1Her
B6.129-Ldlrtm1Her Apoa1tm1Unc
|
abnormal adrenal gland morphology |
J:85174
|
|
abnormal adrenal gland zona fasciculata morphology |
J:85174
|
|
abnormal liver morphology |
J:85174
|
|
decreased cholesterol level |
J:85174
|
|
decreased circulating cholesterol level |
J:85174
|
|
decreased circulating HDL cholesterol level |
J:85174
|
|
decreased circulating LDL cholesterol level |
J:85174
|
|
decreased circulating VLDL cholesterol level |
J:85174
|
|
decreased liver cholesterol level |
J:85174
|
|
increased circulating triglyceride level |
J:85174
|
|
increased pruritus |
J:85174
|
|
skin lesions |
J:85174
|
|
spontaneous skin ulceration |
J:85174
|
|
thick dermal layer |
J:85174
|
|
xanthoma |
J:85174
|
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal eye electrophysiology |
J:136142
|
|
abnormal retina pigment epithelium morphology |
J:136142
|
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6J
|
abnormal aorta bulb morphology |
J:227165
|
|
abnormal heart ventricles weight |
J:227165
|
|
aortic valve stenosis |
J:227165
|
|
decreased cardiac muscle contractility |
J:227165
|
|
increased cardiac output |
J:227165
|
|
increased cardiac stroke volume |
J:227165
|
|
increased circulating cholesterol level |
J:227165
|
|
increased circulating insulin level |
J:227165
|
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
Lepob/Lepob
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal circulating cholesterol level |
J:133453
|
|
atherosclerotic lesions |
J:133453
|
|
decreased circulating HDL cholesterol level |
J:133453
|
|
hypertension |
J:133453
|
|
increased circulating cholesterol level |
J:133453
|
|
increased circulating free fatty acids level |
J:133453
|
|
increased circulating insulin level |
J:133453
|
|
increased circulating LDL cholesterol level |
J:133453
|
|
increased circulating triglyceride level |
J:133453
|
|
obese |
J:133453
|
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
Tg(Ins-Igf2)1Fbos/?
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL
|
abnormal aorta bulb morphology |
J:227165
|
|
abnormal aortic valve morphology |
J:227165
|
|
abnormal cardiovascular system physiology |
J:227165
|
|
abnormal fasting circulating glucose level |
J:227165
|
|
abnormal heart left ventricle morphology |
J:227165
|
|
abnormal heart ventricles weight |
J:227165
|
|
aortic valve stenosis |
J:227165
|
|
aortitis |
J:227165
|
|
calcified aortic valve |
J:227165
|
|
cardiac fibrosis |
J:227165
|
|
cardiac hypertrophy |
J:227165
|
|
decreased cardiac muscle contractility |
J:227165
|
|
heart left ventricle hypertrophy |
J:227165
|
|
increased cardiac output |
J:227165
|
|
increased cardiac stroke volume |
J:227165
|
|
increased circulating cholesterol level |
J:227165
|
|
increased circulating insulin level |
J:227165
|
|
small aortic valve |
J:227165
|
Apobtm2Sgy/Apobtm2Sgy
Ldlrtm1Her/Ldlrtm1Her
Tg(Ins-Igf2)1Fbos/?
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
atherosclerotic lesions |
J:141333
|
|
impaired glucose tolerance |
J:141333
|
|
increased circulating glucose level |
J:141333
|
|
increased circulating insulin level |
J:141333
|
Apobec1tm1Chan/Apobec1tm1Chan
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd
|
abnormal circulating cholesterol level |
J:48202
|
|
decreased circulating triglyceride level |
J:48202
|
|
increased circulating cholesterol level |
J:48202
|
|
increased circulating triglyceride level |
J:48202
|
Apobec1tm1Ddsn/Apobec1tm1Ddsn
Fggtm1Fjc/Fggtm1Fjc
Ldlrtm1Her/Ldlrtm1Her
B6.129-Fggtm1Fjc Apobec1tm1Ddsn Ldlrtm1Her
|
abnormal blood coagulation |
J:132734
|
|
atherosclerotic lesions |
J:132734
|
|
increased circulating LDL cholesterol level |
J:132734
|
|
postnatal lethality, incomplete penetrance |
J:135942
|
Apobec1tm1Ddsn/Apobec1tm1Ddsn
Ldlrtm1Her/Ldlrtm1Her
B6.129-Apobec1tm1Ddsn Ldlrtm1Her
|
abnormal blood coagulation |
J:132734
|
|
atherosclerotic lesions |
J:132734
|
|
decreased partial thromboplastin time |
J:132734
|
|
decreased prothrombin time |
J:132734
|
|
increased circulating antithrombin level |
J:132734
|
|
increased circulating LDL cholesterol level |
J:132734
|
|
increased circulating prothrombin level |
J:132734
|
Apobec1tm1Ddsn/Apobec1tm1Ddsn
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
atherosclerotic lesions |
J:49125
|
|
increased circulating cholesterol level |
J:49125
|
|
increased circulating LDL cholesterol level |
J:49125
|
|
increased circulating triglyceride level |
J:49125
|
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
abnormal lipid homeostasis |
J:67282
|
|
decreased susceptibility to hyperlipidemia |
J:67282
|
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6
|
normal
homeostasis/metabolism phenotype |
J:117317
|
|
increased circulating cholesterol level |
J:117317
|
|
increased circulating HDL cholesterol level |
J:117317
|
|
increased circulating LDL cholesterol level |
J:117317
|
|
increased circulating triglyceride level |
J:117317
|
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
atherosclerotic lesions |
J:129557
|
|
increased susceptibility to atherosclerosis |
J:129557
|
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL
|
abnormal circulating enzyme level |
J:90547
|
|
abnormal circulating protein level |
J:90547
|
|
decreased circulating cholesterol level |
J:90547
|
|
decreased circulating LDL cholesterol level |
J:90547
|
|
decreased circulating triglyceride level |
J:90547
|
|
decreased circulating VLDL cholesterol level |
J:90547
|
|
increased circulating cholesterol level |
J:117317
|
|
increased circulating factor VIII level |
J:90547,
J:117317
|
|
increased circulating HDL cholesterol level |
J:117317
|
|
increased circulating LDL cholesterol level |
J:117317
|
|
increased circulating triglyceride level |
J:117317
|
|
increased circulating von Willebrand factor level |
J:90547
|
|
increased susceptibility to atherosclerosis |
J:90547
|
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
increased circulating cholesterol level |
J:59491
|
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
|
abnormal impulse conducting system conduction |
J:95598
|
|
abnormal response to cardiac infarction |
J:95598
|
|
abnormal ST segment |
J:95598
|
|
abnormal synapse morphology |
J:43043
|
|
abnormal thrombosis |
J:95598
|
|
atherosclerotic lesions |
J:95598
|
|
decreased circulating troponin level |
J:95598
|
|
decreased myocardial infarct size |
J:95598
|
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
abnormal circulating lipid level |
J:146721
|
|
amyloid beta deposits |
J:146721
|
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
abnormal circulating lipid level |
J:146721
|
|
amyloid beta deposits |
J:146721
|
|
increased circulating cholesterol level |
J:146721
|
|
increased circulating triglyceride level |
J:146721
|
Asgr2tm1Her/Asgr2tm1Her
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal lipid homeostasis |
J:21380
|
Ath37CAST/Ei/Ath37CAST/Ei
Ldlrtm1Her/Ldlrtm1Her
involves: CAST/Ei * C57BL/6J
|
decreased susceptibility to atherosclerosis |
J:109792
|
Ath38CAST/Ei/Ath38CAST/Ei
Ldlrtm1Her/Ldlrtm1Her
involves: CAST/Ei * C57BL/6J
|
decreased susceptibility to atherosclerosis |
J:109792
|
Ccl2tm1Rol/Ccl2tm1Rol
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
decreased susceptibility to atherosclerosis |
J:75837
|
|
increased circulating triglyceride level |
J:75837
|
|
increased circulating VLDL cholesterol level |
J:75837
|
Cd1d1tm1Luc/Cd1d1tm1Luc
Ldlrtm1Her/Ldlrtm1Her
B6.129S-Cd1d1tm1Luc Ldlrtm1Her
|
atherosclerotic lesions |
J:110061
|
|
decreased circulating VLDL cholesterol level |
J:110061
|
|
increased susceptibility to atherosclerosis |
J:110061
|
Crotem1Akw/Crotem1Akw
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Crotem1Akw Ldlrtm1Her
|
abnormal artery morphology |
J:331161
|
|
blood vessel inflammation |
J:331161
|
|
normal
skeleton phenotype |
J:331161
|
Crptm1Hjf/Crptm1Hjf
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Crptm1Hjf Ldlrtm1Her
|
atherosclerotic lesions |
J:170409
|
|
decreased circulating LDL cholesterol level |
J:170409
|
|
decreased circulating VLDL cholesterol level |
J:170409
|
|
increased circulating cholesterol level |
J:170409
|
|
increased circulating triglyceride level |
J:170409
|
Ctsstm1Hap/Ctsstm1Hap
Ldlrtm1Her/Ldlrtm1Her
B6.129S-Ctsstm1Hap Ldlrtm1Her
|
abnormal leukocyte migration |
J:82520
|
|
decreased circulating cholesterol level |
J:82520
|
|
decreased circulating LDL cholesterol level |
J:82520
|
|
decreased susceptibility to atherosclerosis |
J:82520
|
|
vascular smooth muscle hypoplasia |
J:82520
|
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
Ldlrtm1Her/Ldlr+
involves: B6.129S4-Cx3cl1tm1Sgs * B6.129S7-Ldlrtm1Her/J
|
decreased circulating cholesterol level |
J:95279
|
|
decreased circulating LDL cholesterol level |
J:95279
|
|
decreased susceptibility to atherosclerosis |
J:95279
|
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
Ldlrtm1Her/Ldlrtm1Her
involves: B6.129S4-Cx3cl1tm1Sgs * B6.129S7-Ldlrtm1Her/J
|
decreased circulating cholesterol level |
J:95279
|
|
decreased circulating LDL cholesterol level |
J:95279
|
|
decreased susceptibility to atherosclerosis |
J:95279
|
|
impaired macrophage chemotaxis |
J:95279
|
Cxcl1tm1Wabo/Cxcl1tm1Wabo
Ldlrtm1Her/Ldlrtm1Her
involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6
|
atherosclerotic lesions |
J:107325
|
|
decreased susceptibility to atherosclerosis |
J:107325
|
Ddr1tm1Wfv/Ddr1tm1Wfv
Ldlrtm1Her/Ldlrtm1Her
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ
|
atherosclerotic lesions |
J:149015
|
|
decreased macrophage cell number |
J:149015
|
Del(11Cxcl16-Zmynd15)1Ifc/Del(11Cxcl16-Zmynd15)1Ifc
Ldlrtm1Her/Ldlrtm1Her
B6.129S-Ldlrtm1Her Del(11Cxcl16-Zmynd15)1Ifc
|
atherosclerotic lesions |
J:123851
|
|
increased apoptosis |
J:123851
|
Esr1tm1.1Mma/Esr1tm1.1Mma
Ldlrtm1Her/Ldlrtm1Her
involves: 129S2/SvPas * 129S7/SvEvBrd
|
abnormal response/metabolism to endogenous compounds |
J:144952
|
|
increased susceptibility to atherosclerosis |
J:144952
|
Esr1tm1Arnal/Esr1tm1Arnal
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd
|
abnormal response/metabolism to endogenous compounds |
J:144952
|
|
increased susceptibility to atherosclerosis |
J:144952
|
Fmo3em1Jmbn/Fmo3em1Jmbn
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal beige fat cell morphology |
J:254352
|
|
decreased susceptibility to diet-induced obesity |
J:254352
|
|
decreased total body fat amount |
J:254352
|
Gpr132tm1Witt/Gpr132tm1Witt
Ldlrtm1Her/Ldlrtm1Her
B6.129-Ldlrtm1Her Gpr132tm1Witt
|
atherosclerotic lesions |
J:100498
|
|
decreased macrophage apoptosis |
J:100498
|
Hhipl1tm1a(KOMP)Wtsi/Hhipl1tm1a(KOMP)Wtsi
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6J * C57BL/6N
|
decreased susceptibility to atherosclerosis |
J:280707
|
Icam1tm1Jcgr/Icam1tm1Jcgr
Ldlrtm1Her/Ldlrtm1Her
involves: 129S4/SvJae * 129S7/SvEvBrd
|
increased neutrophil cell number |
J:69597
|
Icam1tm1Jcgr/Icam1tm1Jcgr
Ldlrtm1Her/Ldlrtm1Her
Vcam1tm1Dmil/Vcam1tm1Dmil
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
decreased circulating cholesterol level |
J:69597
|
|
decreased susceptibility to atherosclerosis |
J:69597
|
|
increased leukocyte cell number |
J:69597
|
|
increased lymphocyte cell number |
J:69597
|
|
increased monocyte cell number |
J:69597
|
|
increased neutrophil cell number |
J:69597
|
Ifngtm1Ts/Ifngtm1Ts
Ldlrtm1Her/Ldlrtm1Her
B6.129S7-Ldlrtm1Her Ifngtm1Ts
|
atherosclerotic lesions |
J:103072
|
|
increased T cell number |
J:103072
|
Ins2Akita/Ins2Akita
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Ins2Akita Ldlrtm1Her
|
decreased body weight |
J:174983
|
|
decreased circulating insulin level |
J:174983
|
|
hyperglycemia |
J:174983
|
|
impaired glucose tolerance |
J:174983
|
|
increased circulating cholesterol level |
J:174983
|
|
increased circulating HDL cholesterol level |
J:174983
|
|
increased circulating LDL cholesterol level |
J:174983
|
|
increased circulating triglyceride level |
J:174983
|
|
increased circulating VLDL cholesterol level |
J:174983
|
|
increased susceptibility to atherosclerosis |
J:174983
|
|
premature death |
J:174983
|
Itgb3tm1Hyn/Itgb3tm1Hyn
Ldlrtm1Her/Ldlrtm1Her
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6
|
atherosclerotic lesions |
J:83615
|
|
decreased circulating cholesterol level |
J:83615
|
|
decreased survivor rate |
J:83615
|
|
increased circulating glucose level |
J:83615
|
|
increased susceptibility to induced morbidity/mortality |
J:83615
|
Lcattm1Hgc/Lcattm1Hgc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * DBA
|
abnormal cholesterol homeostasis |
J:75567,
J:89015
|
|
abnormal circulating protein level |
J:75567
|
|
abnormal lipid homeostasis |
J:75567,
J:89015
|
|
decreased circulating glucose level |
J:89015
|
|
decreased circulating HDL cholesterol level |
J:75567,
J:89015
|
|
decreased circulating insulin level |
J:89015
|
|
decreased circulating LDL cholesterol level |
J:89015
|
|
decreased lipoprotein lipase activity |
J:89015
|
|
normal
homeostasis/metabolism phenotype |
J:75567
|
|
increased circulating cholesterol level |
J:75567
|
|
increased circulating triglyceride level |
J:75567,
J:89015
|
|
increased circulating VLDL cholesterol level |
J:75567,
J:89015
|
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal circulating lipid level |
J:67282
|
|
decreased circulating cholesterol level |
J:67282
|
|
decreased circulating HDL cholesterol level |
J:67282
|
Ldlrtm1Her/Ldlr+
Lepob/Lepob
B6.Cg-Lepob Ldlrtm1Her
|
increased circulating cholesterol level |
J:72027
|
|
increased circulating HDL cholesterol level |
J:72027
|
|
increased liver cholesterol level |
J:72027
|
|
increased liver triglyceride level |
J:72027
|
Ldlrtm1Her/Ldlr+
Tg(H2-K-AKR1B1)1Tj/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
hyperglycemia |
J:100916
|
|
increased susceptibility to atherosclerosis |
J:100916
|
Ldlrtm1Her/Ldlrtm1Her
Lepob/Lepob
B6.Cg-Lepob Ldlrtm1Her
|
abnormal circulating cholesterol level |
J:72027
|
|
atherosclerotic lesions |
J:72027
|
|
hyperlipidemia |
J:72027
|
|
increased circulating cholesterol level |
J:72027
|
|
increased circulating HDL cholesterol level |
J:72027
|
|
increased circulating triglyceride level |
J:72027
|
|
increased liver cholesterol level |
J:72027
|
|
increased liver triglyceride level |
J:72027
|
Ldlrtm1Her/Ldlrtm1Her
Lipctm1Unc/Lipctm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
abnormal lipid level |
J:108412
|
|
decreased circulating corticosterone level |
J:108412
|
|
increased circulating cholesterol level |
J:108412
|
|
increased circulating HDL cholesterol level |
J:108412
|
|
increased circulating LDL cholesterol level |
J:108412
|
Ldlrtm1Her/Ldlrtm1Her
Lipetm1Ishi/Lipetm1Ishi
involves: 129S7/SvEvBrd * C57BL/6J
|
increased susceptibility to atherosclerosis |
J:152385
|
Ldlrtm1Her/Ldlrtm1Her
Lipetm1Ishi/Lipetm1Ishi
Nceh1tm1Ishi/Nceh1tm1Ishi
involves: 129S7/SvEvBrd * C57BL/6J
|
increased susceptibility to atherosclerosis |
J:152385
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
involves: 129S7/SvEvBrd
|
abnormal cholesterol level |
J:67929
|
|
abnormal circulating apolipoprotein E level |
J:67929
|
|
abnormal circulating apolipoprotein level |
J:67929
|
|
increased circulating cholesterol level |
J:67929
|
|
increased circulating LDL cholesterol level |
J:67929
|
|
increased circulating triglyceride level |
J:67929
|
|
increased circulating VLDL cholesterol level |
J:67929
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
impaired macrophage phagocytosis |
J:137404
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
|
abnormal microglial cell physiology |
J:144185
|
|
abnormal response to CNS ischemic injury |
J:144185
|
|
decreased cerebral infarct size |
J:144185
|
|
decreased susceptibility to ischemic brain injury |
J:144185
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
increased circulating cholesterol level |
J:117317
|
|
increased circulating factor VIII level |
J:117317
|
|
increased circulating triglyceride level |
J:117317
|
|
increased circulating von Willebrand factor level |
J:117317
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL
|
abnormal circulating apolipoprotein level |
J:67929
|
|
increased circulating cholesterol level |
J:67929
|
|
increased circulating LDL cholesterol level |
J:67929
|
|
increased circulating triglyceride level |
J:67929
|
|
increased circulating VLDL cholesterol level |
J:67929
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Tagln-cre)1Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL
|
abdominal aorta aneurysm |
J:82871
|
|
abnormal aorta elastic tissue morphology |
J:82871
|
|
aortic aneurysm |
J:82871
|
|
artery occlusion |
J:82871
|
|
atherosclerotic lesions |
J:82871
|
|
dilated aorta |
J:82871
|
|
normal
homeostasis/metabolism phenotype |
J:82871
|
|
increased aorta wall thickness |
J:82871
|
|
increased susceptibility to atherosclerosis |
J:82871
|
|
increased vascular smooth muscle cell proliferation |
J:82871
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Vldlrtm1Her/Vldlrtm1Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
increased circulating factor VIII level |
J:117317
|
Ldlrtm1Her/Ldlrtm1Her
Lrpap1tm1Her/Lrpap1tm1Her
involves: 129S7/SvEvBrd * C57BL/6J
|
abnormal lipid level |
J:43736
|
|
increased circulating cholesterol level |
J:43736
|
|
increased circulating triglyceride level |
J:43736
|
Ldlrtm1Her/Ldlrtm1Her
Magi1Gt(OST33326)Lex/Magi1+
involves: 129S5/SvEvBrd * C57BL/6
|
decreased susceptibility to atherosclerosis |
J:278456
|
Ldlrtm1Her/Ldlrtm1Her
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
abnormal macrophage derived foam cell morphology |
J:142788
|
|
arteriosclerosis |
J:142788
|
|
decreased macrophage cell number |
J:142788
|
|
increased circulating cholesterol level |
J:142788
|
Ldlrtm1Her/Ldlrtm1Her
Mobq5CAST/EiJ/Mobq5CAST/EiJ
B6.CAST-Mobq5CAST/EiJ
|
abnormal circulating VLDL cholesterol level |
J:116503
|
|
decreased circulating cholesterol level |
J:116503
|
|
decreased circulating HDL cholesterol level |
J:116503
|
|
decreased circulating LDL cholesterol level |
J:116503
|
Ldlrtm1Her/Ldlrtm1Her
Mobq6CAST/EiJ/Mobq6CAST/EiJ
B6.CAST-Mobq6CAST/EiJ
|
abnormal food intake |
J:116503
|
|
decreased circulating cholesterol level |
J:116503
|
|
decreased circulating HDL cholesterol level |
J:116503
|
|
decreased circulating LDL cholesterol level |
J:116503
|
|
decreased circulating VLDL cholesterol level |
J:116503
|
|
decreased susceptibility to atherosclerosis |
J:116503
|
|
decreased susceptibility to diet-induced obesity |
J:116503
|
|
improved glucose tolerance |
J:116503
|
Ldlrtm1Her/Ldlrtm1Her
Nceh1tm1Ishi/Nceh1tm1Ishi
involves: 129S7/SvEvBrd * C57BL/6J
|
increased susceptibility to atherosclerosis |
J:152385
|
Ldlrtm1Her/Ldlrtm1Her
Npc1m1N/Npc1m1N
involves: 129S7/SvEvBrd * BALB/c
|
abnormal CNS glial cell morphology |
J:126474
|
|
abnormal Purkinje cell axon morphology |
J:126474
|
|
decreased brain cholesterol level |
J:130969
|
|
decreased corpus callosum size |
J:126474
|
|
decreased Purkinje cell number |
J:126474
|
|
increased cholesterol level |
J:130969
|
|
increased circulating LDL cholesterol level |
J:104996,
J:130969
|
|
premature death |
J:130969
|
Ldlrtm1Her/Ldlrtm1Her
Npc1m1N/Npc1m1N
involves: 129S7/SvEvBrd * BALB/c * C57BL/6
|
increased liver weight |
J:100351
|
|
premature death |
J:100351
|
Ldlrtm1Her/Ldlrtm1Her
Nr0b2tm1.1Mjev/Nr0b2tm1.1Mjev
involves: 129S/SvEvBrd * 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
decreased circulating LDL cholesterol level |
J:149005
|
|
normal
homeostasis/metabolism phenotype |
J:149005
|
|
increased circulating HDL cholesterol level |
J:149005
|
Ldlrtm1Her/Ldlrtm1Her
Nr1h3tm1.1Djm/Nr1h3tm1.1Djm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * DBA
|
abnormal cholesterol homeostasis |
J:184536
|
|
decreased circulating cholesterol level |
J:184536
|
|
decreased circulating triglyceride level |
J:184536
|
|
decreased physiological sensitivity to xenobiotic |
J:184536
|
|
increased liver cholesterol level |
J:184536
|
|
increased susceptibility to atherosclerosis |
J:184536
|
Ldlrtm1Her/Ldlrtm1Her
Nr5a2tm1Sjns/Nr5a2tm1Sjns
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * C57BL/6J * DBA
|
abnormal feces composition |
J:215556
|
|
abnormal sterol level |
J:215556
|
|
normal
cardiovascular system phenotype |
J:215556
|
Ldlrtm1Her/Ldlrtm1Her
Nr5a2tm3.1Sjns/Nr5a2tm3.1Sjns
involves: 129S7/SvEvBrd * C57BL/6J * C57BL/6N
|
abnormal bile secretion |
J:215556
|
|
abnormal cholesterol homeostasis |
J:215556
|
|
decreased cholesterol level |
J:215556
|
|
decreased circulating LDL cholesterol level |
J:215556
|
|
decreased circulating triglyceride level |
J:215556
|
|
decreased susceptibility to atherosclerosis |
J:215556
|
|
increased liver cholesterol level |
J:215556
|
Ldlrtm1Her/Ldlrtm1Her
Olr1tm1Meht/Olr1tm1Meht
involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
decreased circulating HDL cholesterol level |
J:130794
|
|
decreased susceptibility to atherosclerosis |
J:130794
|
|
increased circulating interleukin-10 level |
J:130794
|
|
increased circulating LDL cholesterol level |
J:130794
|
|
increased circulating VLDL cholesterol level |
J:130794
|
Ldlrtm1Her/Ldlrtm1Her
Pcsk9tm1.2Prat/Pcsk9tm1.2Prat
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ
|
increased circulating LDL cholesterol level |
J:169834
|
Ldlrtm1Her/Ldlrtm1Her
Pfn1tm1Wit/Pfn1+
B6.129S-Ldlrtm1Her Pfn1tm1Wit
|
atherosclerotic lesions |
J:140294
|
|
impaired macrophage chemotaxis |
J:140294
|
|
prenatal lethality, incomplete penetrance |
J:140294
|
Ldlrtm1Her/Ldlrtm1Her
Pla2g12ars36523879-C/Pla2g12ars36523879-C
FVB.Cg-Pla2g12ars36523879-C Ldlrtm1Her
|
increased susceptibility to diet-induced aortic fatty streak lesions |
J:290574
|
Ldlrtm1Her/Ldlrtm1Her
Pparatm1Gonz/Pparatm1Gonz
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
decreased lean body mass |
J:84844
|
|
normal
homeostasis/metabolism phenotype |
J:84844
|
|
increased total body fat amount |
J:84844
|
Ldlrtm1Her/Ldlrtm1Her
Scarb1tm1Dhu/Scarb1tm1Dhu
involves: 129S4/SvJae * BALB/c * C57BL/6J
|
atherosclerotic lesions |
J:62371
|
Ldlrtm1Her/Ldlrtm1Her
Scd1ab-2J/Scd1ab-2J
B6.Cg-Ldlrtm1Her Scd1ab-2J
|
abnormal circulating cholesterol level |
J:130278
|
|
abnormal epididymal fat pad morphology |
J:130278
|
|
abnormal fat pad morphology |
J:130278
|
|
abnormal lipid level |
J:130278
|
|
abnormal triglyceride level |
J:130278
|
|
abnormal uterine fat pad morphology |
J:130278
|
|
decreased circulating triglyceride level |
J:130278
|
|
decreased circulating VLDL cholesterol level |
J:130278
|
|
decreased circulating VLDL triglyceride level |
J:130278
|
|
decreased liver triglyceride level |
J:130278
|
|
decreased percent body fat/body weight |
J:130278
|
|
normal
homeostasis/metabolism phenotype |
J:130278
|
|
increased food intake |
J:130278
|
|
normal
liver/biliary system phenotype |
J:130278
|
|
slow postnatal weight gain |
J:130278
|
Ldlrtm1Her/Ldlrtm1Her
Scd1ab-J/Scd1ab-J
B6.Cg-Ldlrtm1Her Scd1ab-J
|
abnormal epididymal fat pad morphology |
J:130278
|
|
abnormal fat pad morphology |
J:130278
|
|
abnormal lipid level |
J:130278
|
|
abnormal uterine fat pad morphology |
J:130278
|
|
decreased circulating cholesterol level |
J:130278
|
|
decreased circulating triglyceride level |
J:130278
|
|
decreased circulating VLDL cholesterol level |
J:130278
|
|
decreased circulating VLDL triglyceride level |
J:130278
|
|
decreased liver triglyceride level |
J:130278
|
|
decreased percent body fat/body weight |
J:130278
|
|
normal
homeostasis/metabolism phenotype |
J:130278
|
|
increased food intake |
J:130278
|
|
normal
liver/biliary system phenotype |
J:130278
|
|
slow postnatal weight gain |
J:130278
|
Ldlrtm1Her/Ldlrtm1Her
Serpine1tm1Mlg/Serpine1tm1Mlg
B6.129S-Serpine1tm1Mlg Ldlrtm1Her
|
atherosclerotic lesions |
J:61287
|
|
increased circulating cholesterol level |
J:61287
|
Ldlrtm1Her/Ldlrtm1Her
Soat1tm1Far/Soat1tm1Far
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J
|
abnormal brain morphology |
J:61147
|
|
abnormal cerebellum morphology |
J:61147
|
|
abnormal dermal layer morphology |
J:61147
|
|
atherosclerotic lesions |
J:61147
|
|
decreased circulating cholesterol level |
J:61147
|
|
skin edema |
J:61147
|
|
skin inflammation |
J:61147
|
|
skin lesions |
J:61147
|
|
thick skin |
J:61147
|
|
xanthoma |
J:61147
|
Ldlrtm1Her/Ldlrtm1Her
Tbx21tm1Glm/Tbx21tm1Glm
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
abnormal interleukin secretion |
J:96110
|
|
abnormal susceptibility to atherosclerosis |
J:96110
|
|
decreased IgG level |
J:96110
|
|
decreased interferon-gamma secretion |
J:96110
|
|
increased circulating cholesterol level |
J:96110
|
|
increased IgM level |
J:96110
|
Ldlrtm1Her/Ldlrtm1Her
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
B6.129-Ldlrtm1Her Tcra-Jtm1Tgi
|
decreased interferon-gamma secretion |
J:140276
|
|
decreased susceptibility to atherosclerosis |
J:140276
|
Ldlrtm1Her/Ldlrtm1Her
Tg(APOC1)1Lmh/?
involves: 129S7/SvEvBrd * C57BL/6
|
increased circulating cholesterol level |
J:65146
|
|
increased circulating triglyceride level |
J:65146
|
|
increased circulating VLDL cholesterol level |
J:65146
|
|
increased circulating VLDL triglyceride level |
J:65146
|
Ldlrtm1Her/Ldlrtm1Her
Tg(APOC3)3707Bres/?
involves: 129S7/SvEvBrd * C57BL/6J * CBA/J
|
atherosclerotic lesions |
J:37861
|
|
increased circulating LDL cholesterol level |
J:37861
|
|
increased circulating VLDL cholesterol level |
J:37861
|
Ldlrtm1Her/Ldlrtm1Her
Tg(APOC3)3707Bres/?
Tg(Mt1-CETP)#Tall/?
involves: 129S7/SvEvBrd * C57BL/6J * CBA/J
|
decreased circulating HDL cholesterol level |
J:37861
|
|
increased circulating LDL cholesterol level |
J:37861
|
|
increased circulating triglyceride level |
J:37861
|
|
increased circulating VLDL cholesterol level |
J:37861
|
Ldlrtm1Her/Ldlrtm1Her
Tg(APOM)NCchr/0
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * CBA
|
abnormal cholesterol homeostasis |
J:130647
|
|
decreased circulating triglyceride level |
J:130647
|
|
decreased susceptibility to atherosclerosis |
J:130647
|
Ldlrtm1Her/Ldlrtm1Her
Tg(APPSWE)2576Kha/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
abnormal long-term spatial reference memory |
J:114480
|
|
abnormal response to new environment |
J:114480
|
|
abnormal spatial learning |
J:114480
|
|
amyloid beta deposits |
J:114480
|
|
amyloidosis |
J:114480
|
|
decreased anxiety-related response |
J:114480
|
|
hyperactivity |
J:114480
|
|
increased circulating cholesterol level |
J:114480
|
|
increased circulating LDL cholesterol level |
J:114480
|
Ldlrtm1Her/Ldlrtm1Her
Tg(CMV-Serpine1)1Dgi/0
B6.Cg-Ldlrtm1Her Tg(CMV-Serpine1)1Dgi
|
atherosclerotic lesions |
J:61287
|
|
increased circulating cholesterol level |
J:61287
|
Ldlrtm1Her/Ldlrtm1Her
Tg(H2-K-AKR1B1)1Tj/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
abnormal circulating cholesterol level |
J:100916
|
|
abnormal macrophage physiology |
J:100916
|
|
hyperglycemia |
J:100916
|
|
increased susceptibility to atherosclerosis |
J:100916
|
Ldlrtm1Her/Ldlrtm1Her
Tg(Il1rn)1Dih/Tg(Il1rn)1Dih
involves: 129S7/SvEvBrd * C57BL/6 * CBA
|
decreased susceptibility to atherosclerosis |
J:76336
|
|
increased circulating cholesterol level |
J:76336
|
|
increased circulating triglyceride level |
J:76336
|
Ldlrtm1Her/Ldlrtm1Her
Tlr2tm1Kir/Tlr2tm1Kir
B6.129-Tlr2tm1Kir Ldlrtm1Her
|
abnormal cellular extravasation |
J:131783
|
|
atherosclerotic lesions |
J:102502,
J:131783
|
|
decreased circulating cholesterol level |
J:102502
|
|
decreased tumor necrosis factor secretion |
J:131783
|
|
increased body weight |
J:102502,
J:131783
|
Ldlrtm1Her/Ldlrtm1Her
Vcam1tm1Dmil/Vcam1tm1Dmil
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
decreased susceptibility to atherosclerosis |
J:69597
|
Ldlrtm1Her/Ldlrtm1Her
Vwftm1Wgr/Vwftm1Wgr
B6.129S-Vwftm1Wgr Ldlrtm1Her
|
decreased susceptibility to atherosclerosis |
J:106677
|
|
impaired leukocyte tethering or rolling |
J:106677
|
Ldlrtm2(AFP)Alb/Ldlrtm2(AFP)Alb
involves: 129S7/SvEvBrd * C57BL/6J
|
no abnormal phenotype detected |
J:132096
|
Soat1tm1Ishi/Soat1tm1Ishi
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal lipid homeostasis |
J:63468
|
|
dry eyes |
J:63468
|
|
increased circulating cholesterol level |
J:63468
|
|
Meibomian gland atrophy |
J:63468
|
|
xanthoma |
J:63468
|
Excel File
Analysis Tools